IONS Ionis Pharmaceuticals Inc
Price (delayed)
$33.03
Market cap
$5.25B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.04
Enterprise value
$6.42B
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and
Highlights
The company's debt fell by 2.7% QoQ and by 2.6% YoY
The company's equity has surged by 52% YoY but it fell by 11% QoQ
IONS's quick ratio is up by 43% year-on-year but it is down by 6% since the previous quarter
The net income has declined by 27% since the previous quarter and by 24% year-on-year
Ionis Pharmaceuticals's EPS has decreased by 25% QoQ and by 19% YoY
Key stats
What are the main financial stats of IONS
Market
Valuations
Earnings
Shares outstanding
158.96M
Market cap
$5.25B
Enterprise value
$6.42B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.86
Price to sales (P/S)
7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.1
Revenue
$705.14M
Gross profit
$693.92M
Operating income
-$475.08M
Net income
-$453.9M
EBIT
-$369.62M
EBITDA
-$347.63M
Free cash flow
-$546.23M
Per share
Balance sheet
Liquidity
EPS
-$3.04
EPS diluted
-$3.04
Free cash flow per share
-$3.65
Book value per share
$3.73
Revenue per share
$4.72
TBVPS
$20.09
Total assets
$3B
Total liabilities
$2.42B
Debt
$1.41B
Equity
$588.35M
Working capital
$2.31B
Debt to equity
2.39
Current ratio
8.47
Quick ratio
7.73
Net debt/EBITDA
-3.35
Margins
Efficiency
Dividend
EBITDA margin
-49.3%
Gross margin
98.4%
Net margin
-64.4%
Operating margin
-67.4%
Return on assets
-15.7%
Return on equity
-100.3%
Return on invested capital
-10%
Return on capital employed
-13.7%
Return on sales
-52.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IONS stock price
How has the Ionis Pharmaceuticals stock price performed over time
Intraday
2.51%
1 week
0.24%
1 month
4.59%
1 year
-23.65%
YTD
-5.52%
QTD
-5.52%
Financial performance
How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$705.14M
Gross profit
$693.92M
Operating income
-$475.08M
Net income
-$453.9M
Gross margin
98.4%
Net margin
-64.4%
The operating margin has dropped by 50% year-on-year and by 46% since the previous quarter
The company's net margin fell by 44% QoQ and by 38% YoY
IONS's operating income is down by 34% year-on-year and by 28% since the previous quarter
The net income has declined by 27% since the previous quarter and by 24% year-on-year
Growth
What is Ionis Pharmaceuticals's growth rate over time
Valuation
What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.86
P/S
7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.1
Ionis Pharmaceuticals's EPS has decreased by 25% QoQ and by 19% YoY
The company's equity has surged by 52% YoY but it fell by 11% QoQ
The stock's price to book (P/B) is 46% less than its last 4 quarters average of 16.5 and 21% less than its 5-year quarterly average of 11.2
The P/S is 14% less than the 5-year quarterly average of 8.1 and 11% less than the last 4 quarters average of 7.9
IONS's revenue is down by 12% QoQ and by 10% YoY
Efficiency
How efficient is Ionis Pharmaceuticals business performance
Ionis Pharmaceuticals's return on sales has shrunk by 63% YoY and by 58% QoQ
Ionis Pharmaceuticals's ROIC has decreased by 45% YoY and by 37% from the previous quarter
IONS's return on assets is down by 27% year-on-year and by 26% since the previous quarter
IONS's return on equity is down by 12% since the previous quarter and by 11% year-on-year
Dividends
What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IONS.
Financial health
How did Ionis Pharmaceuticals financials performed over time
The total assets is 24% greater than the total liabilities
The current ratio rose by 44% year-on-year but it has declined by 4.9% since the previous quarter
IONS's quick ratio is up by 43% year-on-year but it is down by 6% since the previous quarter
The company's debt is 139% higher than its equity
The company's equity has surged by 52% YoY but it fell by 11% QoQ
Ionis Pharmaceuticals's debt to equity has decreased by 36% YoY but it has increased by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.